Skip to content

MeiraGTx Holdings plc MGTX License — Revenue

Other product segments

Related Party Service Revenue
$293K-84.8%

Similar metrics at other companies

Stoke Therapeutics, Inc. logo
STOKLicense — Revenue
$2.88M-60.9%
Nurix Therapeutics, Inc. logo
NRIXLicense revenue — Revenue
$30M
Rhythm Pharmaceuticals, Inc. logo
RYTMLicense revenue — Total revenues
$0+100%
Viridian Therapeutics, Inc. logo
VRDNLicense — Total revenues
$6K
ACI Worldwide logo
ACIWLicense — Revenue
$88.04M+4.2%
Supernus Pharmaceuticals logo
SUPNLicense — Revenue recognized
$20M+433%

Other financials

Income statement

See full
Revenue$293.0K-84.8%
Operating income-$40.8M+1.9%
Net income-$46.3M-15.8%
EPS (diluted)-$0.57-11.8%

Balance sheet

See full
Cash & equivalents$71.5M+7.5%
Total debt$62.7M-22.5%
Total equity-$58.1M-276%
Total assets$244.7M+9.2%

Cash flow

See full
Operating cash flow$17.8M+148%
CapEx$2.0M+17.4%
Free cash flow$15.8M+141%

Valuation

See full
Market cap$1.07B+111%
Enterprise value$1.07B+103%
P/S13.5×-1.3×

Profitability

See full
Operating margin-597.9%-207pp
Net margin-615.3%
FCF margin-441.5%-126pp

Returns & leverage

See full
Return on equity-379.5%
Debt / equity27.2×+26.1×
Current ratio0.5×-1.0×

Where this comes from

Reported directly by MeiraGTx Holdings plc in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: MeiraGTx Holdings plc’s 10-K, filed March 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about MeiraGTx Holdings plc's license — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MeiraGTx Holdings plc's license — revenue?
MeiraGTx Holdings plc (MGTX) reported license — revenue of $18.75M in Q4 2025.
What does license — revenue mean?
This metric represents the total revenue recognized from licensing agreements, intellectual property rights, or technology transfer arrangements within the company's gene therapy portfolio. It reflects the commercial success of monetizing proprietary research and development assets through partnerships or collaborative agreements. Tracking this revenue stream is essential for evaluating the company's ability to generate non-dilutive capital and validate the market potential of its clinical-stage pipeline.